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Sir,
It is with great interest that I read the article by Thompson Coon
et al, as I agree with the authors that there is a need for performing
indirect treatment comparisons in order to offer guidance on
therapy decisions to oncologists.
As this is an important topic, I would like to outline some methodo-
logical issues that are related to the Thompson Coon et al analysis.
P-VALUE CALCULATION APPROACH
Using a one-sided t-test to calculate a P-value, as performed by
Thompson Coon et al (2009), has to be regarded as a questionable
approach, as two-sided t-tests are the common approach in clinical
research and should be expected in such an analysis by the clinical
readers of BJC. Even if this unusual approach is explicitly described,
the findings in the abstract are misleading, as they seem to show
statistical proof on a significant difference comparing sunitinib
(SUN) with bevacizumab (BEV)þinterferon alpha-2a (IFN) in first-
line metastatic renal cell carcinoma. To elaborate, Thompson Coon
et al (2009) simply calculated the P-value as the proportion of
Bayesian Markov Chain Monte-Carlo (MCNC) trials in which the
hazard ratio (HR) for any comparison exceeded the indirect
comparison HR of ‘1’. In contrast, the authors should have reported
the number of instances in which the lower confidence limit of HR
for each iteration exceeded 1 or simply tested the hypothesis that
Log(HR)¼0, using the standard z-statistic. If a valid statistical
method is used (e.g., that from Snedecor and Cochran, 1989), this
would have led to a P-value that indicates a non-significant
difference between SUN and BEVþIFN. This non-significant
difference between both therapy options using a two-sided t-test is
obvious, as the indirect comparison HR of SUN vs BEVþIFN
exceeded ‘1’ in the upper 95% confidence interval limit.
MCMC SAMPLING
The authors performed an indirect comparison using Bayesian
MCMC sampling, with IFN as a common comparator, adopting a
fixed-effect model. Point estimates and 95% confidence intervals
were calculated from 100000 simulated draws from the posterior
distribution after a burn-in of 10000 iterations.
This up-sampling of point estimates has most likely led
to more narrow confidence intervals that may be responsible
for possible significant differences between treatments. Taking
into account the fact that the SUN pivotal trial included
750 patients (Motzer et al, 2007) and the pooled BEV trials
included 1381 patients (Escudier et al, 2007; Rini et al, 2008),
the chosen number of simulation samples overpowers that
of base trials. In general, it is recommended to either select
the number of iterations on the total number of patients or
the expected number of patients in the country of interest;
hence, around 2000 simulation samples would have been an
appropriate choice.
INDIRECT COMPARISON APPROACH
Although the authors name the Bucher et al methodology (Bucher
et al, 1997) as ‘a fairly simple analytical approach’, the Canadian
Agency for Drugs and Technologies in Health (CADTH) (Wells
et al, 2009a) and others (Tudur et al, 2002; Song et al, 2003) have
identified this method as the most suitable approach for
performing indirect treatment comparisons. The Bucher et al
methodology is to be regarded as the gold-standard method for
indirect treatment comparisons, as it is transparent and excludes
the risk of producing misleading results that may be produced by
up-sampling the power of base trials.
BASE DATA USED
An adequate indirect comparison approach should consider
pivotal trials performed under similar conditions as comparable,
and assume highest data quality (independent radiology review of
PFS, blinded as opposed to the open-label study).
If the author pooled a pivotal trial (Escudier et al, 2007) and an
investigator-initiated trial (Rini et al, 2008) for BEVþIFN, the
same approach should have been applied for SUN using the pivotal
trial (Motzer et al, 2007) and first-line outcomes from the
expanded access study (Gore et al, 2007).
OWN FINDINGS
According to our own ongoing research that uses the gold-standard
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www.bjcancer.compivotal trials (SUN vs IFN 0.538; 95% CI: 0.439–0.658 (Motzer
et al, 2007), BEVþIFN vs IFN 0.571 (0.450–0.723) (Escudier et al,
2009)), there is no statistically significant evidence for a difference
in efficacy with respect to PFS between SUN and BEVþIFN-a. The
indirect comparison HR was 0.942 (95% CI 0.69–1.29; two-sided
t-test P¼0.71).
CADTH offers an open-access tool (Wells et al, 2009b) that enables
researchers worldwide to re-perform and validate our findings.
As indirect treatment comparisons are increasingly used in
medical decision making, I considered it important to draw
attention to methodological issues for the benefit of those both
performing and using the results of these comparisons.
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